Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Momo Hirata"'
Autor:
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential p
Externí odkaz:
https://doaj.org/article/8a23af9f1a724ed69d43d34d79739f8c
Autor:
Yukari Tsuchino, Tatsuyuki Chiyoda, Mitsuyo Jisaka, Tomomi Sakamaki, Momo Hirata, Mio Takahashi, Takuma Yoshimura, Kensuke Sakai, Michiko Wada, Wataru Yamagami
Publikováno v:
Gynecologic Oncology Reports, Vol 54, Iss , Pp 101444- (2024)
Brain metastasis from ovarian cancer is a very rare condition with a poor prognosis. However, due to its rarity, there is no established treatment strategy. We present a case series of brain metastasis with ovarian cancer, focusing on two long-term s
Externí odkaz:
https://doaj.org/article/22d9523b802b4c25bc99eaf822fce6cb
Autor:
Momo Hirata, Yu Hara, Hiroaki Fujii, Kota Murohashi, Yusuke Saigusa, Shiqi Zhao, Miyu Kobayashi, Ryo Nagasawa, Yoichi Tagami, Ami Izawa, Yukiko Otsu, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background The ILD-GAP scoring system is known to be useful in predicting prognosis in patients with interstitial lung disease (ILD). An elevated monocyte count was associated with increased risks of IPF poor prognosis. We examined whether t
Externí odkaz:
https://doaj.org/article/8ac8e50f41ef409e95e09ec1c5a8f4a9
Autor:
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko
Publikováno v:
European Clinical Respiratory Journal, Vol 11, Iss 1 (2024)
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre, r
Externí odkaz:
https://doaj.org/article/3a61695cb0444719be9e00172eb6d4dd
Autor:
Yoichi Tagami, Yu Hara, Kota Murohashi, Ryo Nagasawa, Hiroaki Fujii, Ami Izawa, Aya Yabe, Yusuke Saigusa, Miyu Kobayashi, Masafumi Shiida, Momo Hirata, Yukiko Otsu, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Serum heme oxygenase (HO)-1 level has been reported as a clinically reliable diagnostic biomarker for acute exacerbation of interstitial lung disease (ILD); however, its utility for predicting mortality among these patients is unclear. Serum
Externí odkaz:
https://doaj.org/article/66c3840d6e1d40528da6d93c65c5882f
Autor:
Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayashi, Yuuki Higashino, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Kohei Somekawa, Ayami Kaneko, Ryo Nagasawa, Sousuke Kubo, Katsushi Tanaka, Kota Murohashi, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0299760 (2024)
BackgroundImmune checkpoint inhibitors (ICIs) have improved outcomes in cancer treatment but are also associated with adverse events and financial burdens. Identifying accurate biomarkers is crucial for determining which patients are likely to benefi
Externí odkaz:
https://doaj.org/article/2eee71d6b23e44f4881ae7b437149737
Autor:
Chisato Kamimaki, Nobuaki Kobayashi, Momo Hirata, Kohei Somekawa, Nobuhiko Fukuda, Sousuke Kubo, Seigo Katakura, Shuhei Teranishi, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1726-1734 (2021)
Abstract Background Immune checkpoint inhibitors are a standard treatment for advanced lung cancer, although it remains important to identify biomarkers that can accurately predict treatment response. Immune checkpoint inhibitors enhance the antitumo
Externí odkaz:
https://doaj.org/article/d84a8207a6c34ec28c0240f6c21be844
Autor:
Momo Hirata, Keita Hasegawa, Yoshifumi Kasuga, Akina Haiden, Satoru Ikenoue, Ryo Yamamoto, Mamoru Tanaka, Junichi Sasaki, Daigo Ochiai
Publikováno v:
Taiwanese Journal of Obstetrics & Gynecology, Vol 60, Iss 3, Pp 579-580 (2021)
Externí odkaz:
https://doaj.org/article/80b50070a6fc4f118466afbc30aa8d76
Autor:
Yu Hara, Hongmei Piao, Kohei Somekawa, Takeshi Kaneko, Nobuhiko Fukuda, Masaki Yamamoto, Makoto Kudo, Momo Hirata, Sousuke Kubo, Seigo Katakura, Nobuaki Kobayashi, Keisuke Watanabe, Nobuyuki Horita, Chisato Kamimaki, Shuhei Teranishi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1726-1734 (2021)
Thoracic Cancer
Thoracic Cancer
Background Immune checkpoint inhibitors are a standard treatment for advanced lung cancer, although it remains important to identify biomarkers that can accurately predict treatment response. Immune checkpoint inhibitors enhance the antitumor T‐cel
Autor:
Sousuke Kubo, Seigo Katakura, Kohei Somekawa, Masaki Yamamoto, Yu Hara, Momo Hirata, Chisato Kamimaki, Nobuaki Kobayashi, Hiroko Aiko, Shuhei Teranishi, Keisuke Watanabe, Makoto Kudo, Takeshi Kaneko
Publikováno v:
Anticancer Research. 40:3889-3896
Background/aim Immune checkpoint inhibitors (ICIs) have an important role in lung cancer therapy. Although the programmed cell death protein-1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden are known prognostic factors, they are ins